Document Detail

Description of patients with midgut carcinoid tumours: clinical database from a Danish centre.
MedLine Citation:
PMID:  17708366     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: We have initiated a clinical database of patients with neuroendocrine tumours (n = 132). Data on patients with well-differentiated endocrine carcinoma (WHO classification) previous classified as midgut carcinoid patients, are presented. PATIENTS AND METHODS: Retrospectively, 56 patients with midgut carcinoid tumours were evaluated with respect to symptoms, primary tumour size, metastases, tumour markers, treatment and survival. RESULTS: Flushing was described in 29%, diarrhoea in 52%, abdominal pain in 34%, bronchial constriction in 2% and carcinoid heart disease in 4% of the patients. Fifty-two percent had liver metastases at referral. Twenty-seven percent were considered to have had radical surgery. Patients not considered for radical surgery and patients with liver metastases had significantly higher tumour marker levels (serum chromogranin A (CgA), serum serotonin and urinary 5-hydroxyindolic acid (5-HIAA)) compared to radically-operated patients and to patients without liver metastases (p<0.05, respectively). For all the midgut carcinoid tumour patients the overall 5-year survival rate was 72%. The radically-operated patients had a 5-year survival rate of 100% (other death causes excluded). The patients with normal CgA or <5 liver metastases at referral had a 100% 5-year survival rate. The patients with <5 liver metastases had a significantly better 5-year survival rate compared to patients with multiple liver metastases (100% vs. 50%, p<0.05). CONCLUSION: This group of patients exhibited the same characteristic clinical features with similar survival as reported from other specialised centres. Radical surgery, normal CgA level and <5 liver metastases indicated a good prognosis and patients with <5 liver metastases had a significantly better survival compared to patients with multiple liver metastases.
Karen Marie Nykjaer; Henning Grønbaek; Dennis Tønner Nielsen; Peer Christiansen; Lone Bording Astrup
Related Documents :
11019996 - Induction of type 1 plasminogen activator inhibitor in human liver ischemia and reperfu...
9224306 - Surgery for metachronous solitary liver metastases of renal cell carcinoma.
17912586 - Outcome after hepatic resection of solitary liver metastasis from colorectal cancer in ...
20571276 - Treatment of metachronous and simultaneous liver metastases of pancreatic cancer.
24076756 - Prognostic factors associated with decreased survival in patients with acinic cell carc...
3531726 - Bilateral ovarian involvement as the only manifestation of malignant lymphoma.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  In vivo (Athens, Greece)     Volume:  21     ISSN:  0258-851X     ISO Abbreviation:  In Vivo     Publication Date:    2007 Jul-Aug
Date Detail:
Created Date:  2007-08-21     Completed Date:  2007-09-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8806809     Medline TA:  In Vivo     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  679-84     Citation Subset:  IM    
Department of Medicine V (Hepatology and Gastroenterology), Aarhus University Hospital, Aarhus, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carcinoid Heart Disease / mortality,  surgery
Carcinoid Tumor / mortality*,  secondary*,  surgery
Databases, Factual
Denmark / epidemiology
Endocrine Gland Neoplasms / mortality*,  pathology*,  surgery
Follow-Up Studies
Liver Neoplasms / mortality,  secondary
Middle Aged
Retrospective Studies
Survival Analysis
Tumor Markers, Biological
Reg. No./Substance:
0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in inva...
Next Document:  Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculat...